Navigation Links
PCI Biotech Commences Phase I/II Trials of Amphinex(R)
Date:8/24/2009

OSLO, August 24 /PRNewswire/ -- PCI Biotech Holding ASA, the Norwegian drug delivery company focusing on effective delivery of cancer therapeutics, today announced that the first patient has received treatment in the Phase I/II trial with the lead candidate Amphinex(R), which uses a new approach called photochemical internalisation. The patient was treated at the University College Hospital (UCH) in London. PCI's proprietary photosensitiser Amphinex(R) is in this study combined with the therapeutic agent bleomycin. When activated by light, Amphinex(R) promotes effective delivery of large therapeutic molecules such as bleomycin through triggered endosomal release. The trial will investigate a broadly representative spectrum of cancers including head and neck cancer and breast cancer, to demonstrate the safety and potential of this new approach.

The primary objective of this study is to assess the maximum tolerated dose of Amphinex(R), in PCI treatment with bleomycin. Secondary objectives include determination of the antitumor activity of Amphinex(R) when used in combination with bleomycin, as well as its pharmacokinetics.

Colin Hopper, Principal Investigator at UCH, said: "At UCH we are dedicated to high quality patient care and we have extensive experience in the use of photodynamic therapy to treat cancer patients. PCI is a very exciting new approach in photodynamic medicine that has shown great promise in preclinical studies. We are very proud of being the first centre to move this new technology into the clinic."

Per Walday CEO of PCI Biotech, said: "This first in man trial is an important step forward for the company. We are confident that our approach addresses one major challenge in oncology - how to deliver therapeutics with large enough loads to effectively destroy tumours while at the same time reducing the risk of damaging healthy cells. Bleomycin is ideal for demonstrating this - there is no doubt about its therapeutic potential, but until now delivery problems and associated toxicity have prevented the realisation of its full potential. We expect to have the first preliminary results of the trial early in 2010."

In addition, whilst our main initial focus is cancer, we strongly believe the PCI technology also has potential to improve the effect of emerging treatments such as gene therapy and therapies based on nanotechnology or on biotechnological principles. In particular, we are looking at siRNA through projects funded by EU and by the Norwegian Research Council."


'/>"/>
SOURCE PCI Biotech
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. TriLink BioTechnologies to Sponsor GIVING HUNGER THE BLUES, a Benefit Concert to Help Alleviate Hunger in San Diego County
2. CBI Hosts 5th Annual Pharma/Biotech Enterprise Governance, Risk and Controls Congress
3. Swedish-American Life Science Summit (SALSS) to Address Major Issues Including Healthcare Reform, Synthetic Biology and Innovative Financing for Biotechs
4. Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results
5. Biotech Hot in July Driven by Positive Drug Data and Acquisitions
6. Cardinal Health Completes Biotech Acquisition
7. Oncolytics Biotech(R) Inc. Announces 2009 Second Quarter Results
8. PROLOR Biotech Acquires License Option from Yeda for Development of Long-Acting Anti-Obesity Drug
9. Oncolytics Biotech Inc. Successfully Completes 100-Litre cGMP Production of REOLYSIN(R)
10. PROLOR Biotech Announces $10 Million Preferred Stock Line From Members of The Frost Group
11. Growing Awareness and Increased Investments Lead to Growth of Biotechnology Applications in the Food & Beverage and Dietary Supplements Sector, Reveals Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only ... Center and will showcase its product’s latest features from June 26 to June ... scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
(Date:6/23/2016)... June 23, 2016 ReportsnReports.com ... report to its pharmaceuticals section with historic and ... and much more. Complete report on ... pages, profiling 15 companies and supported with 261 ... http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . The Global Cell ...
Breaking Biology Technology:
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:3/29/2016)... RATON, Florida , March 29, 2016 ... or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are ... DNA in ink used in a variety of writing ... theft. Buyers of originally created collectibles from athletes on ... through forensic analysis of the DNA. ...
Breaking Biology News(10 mins):